According to a new study, the rates of cerebral venous sinus thrombosis (CVST) are higher among patients infected with COVID-19 compared to those among people after getting vaccinated with either the AstraZeneca or the Johnson & Johnson vaccine.

According to the study, as of April 14, 2021, 77 CVST cases were reported among 21,200,000 recipients of AstraZeneca vaccine by the UK Medicines and Healthcare Products Regulatory Agency, translating to 3.6 per million. As of April 13, 2021, the Centers for Disease Control and Prevention reported only 6 cases of CVST among 6.85 million vaccinated individuals (0.9 per million), and in the SVIN COVID-19 registry, three out of 14,483 patients hospitalized with COVID-19 had CVST (207.1 per million).

The investigators concluded that CVST is rare in the general population and after adenovirus-based COVID-19 vaccination, while it appears to occur several times more often in hospitalized COVID-19 patients. The findings were published online in the Journal of the American College of Cardiology… (Medscape)